Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractHepatitis E virus (HEV) infection has been identified as a cause of graft hepatitis in liver transplant recipients. The true frequency and clinical importance of HEV infections after liver transplantations is a matter of debate. It is proposed that consumption of HEV-contaminated undercooked meat is a main source for HEV infections in developed countries--which might also account for some hepatitis E cases after organ transplantation. However, HEV is also transmitted by transfusion of blood products, likely representing a previously underestimated risk particularly for patients in the transplant setting. HEV infection can take chronic courses in immunocompromised individuals, associated in some cases with rapid progression to cirrhosis within 1-2 years of infection. Diagnosis in transplanted patients is based on HEV RNA testing as antibody assays are not sensitive enough. Selection of immunosuppressive drugs is important as different compounds may influence viral replication and the course of liver disease. Ribavirin has antiviral activity against HEV and should be administered for at least three months in chronically infected individuals; however, treatment failure may occur. HEV infections have also been linked to a variety of extrahepatic manifestations both during and after resolution of infection. In this review we summarize the emerging data on hepatitis E with a particular focus on the importance of HEV infections for liver transplant recipients.
CitationThe impact of hepatitis E in the liver transplant setting. 2014, 61 (6):1418-29 J. Hepatol.
JournalJournal of hepatology
The following license files are associated with this item:
- Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients.
- Authors: Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, Schlue J, Strassburg CP, Lehner F, Raupach R, Bremer B, Magerstedt P, Cornberg M, Seehusen F, Baumgaertner W, Klempnauer J, Izopet J, Manns MP, Grummer B, Wedemeyer H
- Issue date: 2010 Jan
- Course and treatment of chronic hepatitis E virus infection in lung transplant recipients.
- Authors: Pischke S, Greer M, Hardtke S, Bremer B, Gisa A, Lehmann P, Haverich A, Welte T, Manns MP, Wedemeyer H, Gottlieb J, Hepatitis E study group
- Issue date: 2014 Apr
- Hepatitis E virus infection in hematopoietic stem cell transplant recipients.
- Authors: van der Eijk AA, Pas SD, Cornelissen JJ, de Man RA
- Issue date: 2014 Aug
- Relevance of chronic hepatitis E in liver transplant recipients: a real-life setting.
- Authors: Galante A, Pischke S, Polywka S, Luetgehethmann M, Suneetha PV, Gisa A, Hiller J, Dienes HP, Nashan B, Lohse AW, Sterneck M
- Issue date: 2015 Aug
- Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.
- Authors: Cordts SE, Schneble L, Schnitzler P, Wenzel JJ, Vinke T, Rieger S, Fichtner A, Tönshoff B, Höcker B
- Issue date: 2018 Jul